Search company, investor...
Search
Sangamo Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

sangamo.com

Founded Year

1995

Stage

PIPE | IPO

Total Raised

$16.19M

Market Cap

0.76B

Stock Price

4.90

About Sangamo Therapeutics

Sangamo Therapeutics is focused on translating science into genomic medicines with the potential to transform patients' lives using the company's platform technologies in genome editing, gene therapy, gene regulation, and cell therapy.

Sangamo Therapeutics Headquarters Location

7000 Marina Blvd

Brisbane, California, 94005,

United States

510-970-6000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Sangamo Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Sangamo Therapeutics in 1 CB Insights research brief, most recently on Aug 31, 2021.

Article Thumbnail

Aug 31, 2021

What Is CRISPR?

Expert Collections containing Sangamo Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sangamo Therapeutics is included in 3 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Sangamo Therapeutics Patents

Sangamo Therapeutics has filed 315 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/26/2018

9/27/2022

Transcription factors, Molecular biology, Clusters of differentiation, Genetics, Biotechnology

Grant

Application Date

10/26/2018

Grant Date

9/27/2022

Title

Related Topics

Transcription factors, Molecular biology, Clusters of differentiation, Genetics, Biotechnology

Status

Grant

Latest Sangamo Therapeutics News

Pfizer and Sangamo re-open recruitment for gene therapy in hemophilia A

Sep 26, 2022

US pharma giant Pfizer (NYSE: PFE) and biotech company Sangamo Therapeutics (Nasdaq: SGMO) have re-opened recruitment for the AFFINE study. This Phase III trial is evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. Pfizer previously paused this trial when some of the patients experienced FVIII activity greater than 150% following treatment. One participant with elevated… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK

Sangamo Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sangamo Therapeutics Rank

  • When was Sangamo Therapeutics founded?

    Sangamo Therapeutics was founded in 1995.

  • Where is Sangamo Therapeutics's headquarters?

    Sangamo Therapeutics's headquarters is located at 7000 Marina Blvd, Brisbane.

  • What is Sangamo Therapeutics's latest funding round?

    Sangamo Therapeutics's latest funding round is PIPE.

  • How much did Sangamo Therapeutics raise?

    Sangamo Therapeutics raised a total of $16.19M.

  • Who are the investors of Sangamo Therapeutics?

    Investors of Sangamo Therapeutics include AAC Capital Partners, LODH Private Equity Partners, JAFCO Life Science Investment, The Stephens Group, Palladin Group and 3 more.

  • Who are Sangamo Therapeutics's competitors?

    Competitors of Sangamo Therapeutics include Larimar Therapeutics, La Jolla Pharmaceutical Company, Sirnaomics, Dicerna Pharmaceuticals, CODA Biotherapeutics, Apitope, Sagimet Biosciences, Pfenex, Cathay Industrial Biotech, Panacea Pharmaceuticals and 52 more.

You May Also Like

B
Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

Bar Harbor BioTechnology Logo
Bar Harbor BioTechnology

Bar Harbor Biotech is a life sciences company spun-out from The Jackson Laboratory to develop gene expression products and services. Bar Harbor Biotech's technology focuses on real-time quantitative polymerase chain reaction (PCR), an established technique for gene expression used in disease research, molecular diagnostics, drug discovery, and other fields of biology research.

A
Aliva Biopharmaceuticals

Aliva Biopharmaceuticals is a company that received a SBIR Phase I grant for a project entitled: Humanized Mouse Ig system employing BAC. Their research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

A
Athena Environmental Sciences

AthenaES specializes in the development and commercialization of advanced biotechnology-based products. Throughout its eleven year history, the company has maintained a broad perspective for applying its core competency, the use of proteins and enzymes for commercial applications, to develop products. As such, the company currently markets its products and services through two business units and maintains an exploratory R&D group. The Athena Enzyme Systems Group aims to provide specialty reagents and proteins for the production and recovery of recombinant proteins along with providing contract R&D services. Products include: Expression Media, Serum-free Media, Protein Refolding kits, and the PDQ Protease Assay. This business unit also aims to provide specialized contract research, development and manufacturing services for the production of recombinant proteins. The Athena Environmental Services Group designs, develops and manufactures environmentally responsible products. Products developed include: The Bilge Pill, a biodegradable cleaning product for the removal of oil in boat bilges, and a plant nutrient supplement used in hydroponics, hobby gardens and horticulture that replaces conventional fertilizers, and the Sting Thing, an enzyme-based invertebrate sting treatment product. More recently, this group developed and has introduced a water-soluble, reversible glue, MagiGlue. The Athena Exploratory Science Group has the mission to pursue research with the potential for commercial, environmental and social impact. These projects are far reaching in their scope and represent high risk, high-value projects.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.